A 50-year-old diabetic and hypertensive male patient is reported who had ticlopidine-induced marrow aplasia partially responsive to colony-stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine. There is no consensus on the treatment of ticlopidine-induced marrow aplasia. Although many cases are reported to recover with colony-stimulating factors and corticosteroids, others are unresponsive or partially responsive. Our patient also did not completely respond to these medications, but was successfully treated with cyclosporine alone. Alone or in combination with corticosteroids, cyclosporine is an effective drug of choice for the resistant patients.
1. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. Circulation1990;82:17-17.
2.
2. Arcan JC, Blanchard J, Boissel JP, et al. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology1988;39:802-802.
3.
3. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med1998;129:394-394.
4.
4. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. Ticlopidine Aspirin Stroke Study Group. NEngl JMed1989;321:501-501.
5.
5. Mataix R, Ojeda E, Perez MDC, et al. Ticlopidine and severe aplastic anemia. Br J Haematol1992;80:125-125.
6.
6. Ono K, Kurohara K, Yoshihara M. Agranulocytosis caused by ticlopidine and its mechanism. Am J Haematol1991;37:239-239.
7.
7. Resegotti L, Pistone MA, Testa D. Culture de moelle chez les sujets traites par la Ticlopidine. Nouv Rev Franc d'Hematol1985;27:19-19.
8.
8. Yeh SP, Hsueh EJ, Wu H, et al. Ticlopidine-associated aplastic anemia. A case report and review of literature. Ann Hematol1998;76:87-87.
9.
9. Murray JC, Kelly MA, Gorelick PB. Ticlopidine. A new antiplatelet agent for the secondary prevention of stroke. Clin Neuropharmacol1994;17:23-23.
10.
10. Troussard X, Mayo P, Mosquet B, et al. Ticlopidine and severe aplastic anemia. Br J Hematol1992;82:779-779.
11.
11. Mallet L, Mallet J. Ticlopidine and fatal aplastic anemia in an elderly women. Ann Pharmacother1994;28(10):1169-1169.
12.
12. Kao TW, Hung CC, Chen YC, et al. Ticlopidine-induced aplastic anemia: Report of three Chinese patients and review of the literature. Acta Hematol1997;98(4):211-211.
13.
13. Vinod A Pullarkat, Hyan Rho, Joyce L, et al. Ticlopidineinduced aplastic anemia: Development of chromosomal abnormalities and response to immunosuppressive therapy. Am J Hematol2000;63:141-141.
14.
14. Bahug H, Lee JH, Suh C, et al. Severe aplastic anemia induced by ticlopidine: Report of two cases. J Korean Med Sci1998;13(5):541-541.
15.
15. Taher A, Ammash Z, Dabajah B, et al. Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: Case report and literature review. Am J Hematol2000;63(2):90-90.
16.
16. Sari R, Sevinc A, Buyukberber S. Ticlopidine-induced severe agranulocytosis after the placement of coronary artery stent-a case report. Angiology2000;51(7):591-591.
